EP1686974A1 - Extended release dosage forms of bupropion hydrochloride - Google Patents

Extended release dosage forms of bupropion hydrochloride

Info

Publication number
EP1686974A1
EP1686974A1 EP04798903A EP04798903A EP1686974A1 EP 1686974 A1 EP1686974 A1 EP 1686974A1 EP 04798903 A EP04798903 A EP 04798903A EP 04798903 A EP04798903 A EP 04798903A EP 1686974 A1 EP1686974 A1 EP 1686974A1
Authority
EP
European Patent Office
Prior art keywords
dosage form
extended release
release dosage
core
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04798903A
Other languages
German (de)
French (fr)
Inventor
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1686974A1 publication Critical patent/EP1686974A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Definitions

  • the present invention relates to extended release dosage forms of bupropion hydrochloride and processes for their preparation.
  • Bupropion hydrochloride is a well-known antidepressant and non-nicotine aid to smoking cessation. It has been observed that bupropion hydrochloride when taken in an immediate release dosage form has the risk of inducing seizures in patients. This side effect is attributed to the sudden high peak plasma concentration produced by these immediate release dosage forms. The incidences of seizures can be subsided by designing a dosage form of bupropion hydrochloride with extended release properties so that sudden high peak plasma concentration is avoided.
  • 4,687,660 discloses a controlled release dosage form powered by an osmotic pumping mechanism.
  • the dosage form comprises a core containing bupropion hydrochloride and osmotic enhancing agent in an amount equal to or greater than bupropion hydrochloride.
  • the core is coated with a semi-permeable polymeric film consisting of water insoluble, water permeable polymer, channeling agents which dissolve in the gastrointestinal fluids and provide passage for the release of drug from the core.
  • the drug release from the core is driven by osmotic pressure.
  • This type of dosage form has the disadvantage that there is always a risk of dose dumping in case too much pressure is built up in the core and the dosage form may burst releasing the entire drug at once which may also precipitate a seizure.
  • an extended release dosage form of bupropion hydrochloride includes a core, and a coating on the core.
  • the core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents.
  • the coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients.
  • Embodiments of the dosage form may include one or more of the following features.
  • a seal coating may be included between the core and the coating surrounding the core.
  • the seal coating may include one or more water soluble polymers for example, hydroxypropylmethylcellulose and hydroxypropylcellulose.
  • the one or more pharmaceutically acceptable excipients may include one or more binders, fillers, plasticizers, and lubricants /glidants.
  • the binders may include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof.
  • the fillers may be microcrystalline cellulose.
  • the lubricants may include one or more of magnesium stearate, stearic acid, and glyceryl behenate.
  • the plasticizers may include one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1,2-propyleneglycol, dibutylsebacate, diethylsebacate, and mixtures thereof.
  • the coating on the core may include one or more polymers that may be permeable to gastrointestinal fluids but insoluble in the same.
  • polymers include cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like.
  • an enteric coating may be applied outside the coating surrounding the core.
  • the enteric coating may include one or more enterosoluble polymers.
  • the enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine.
  • the enteric layer may serve to protect the drug from gastric contents.
  • enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
  • the coatings may optionally contain one or more excipients such as plasticizers, lubricants, glidant anti-adherents for example, magnesium stearate, talc, colloidal silicon dioxide, silicon dioxide, inert fillers, and pigments. Silicon dioxide may additionally function as a wicking agent for fluids from the external media into the core.
  • an extended release dosage form of bupropion hydrochloride includes a core, a first coating on the core and a second enteric coating surrounding the first coating.
  • the core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents.
  • the first coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients.
  • the second enteric coating surrounds the first coating and includes one or more enterosoluble polymers and, optionally, one or more pharmaceutically acceptable excipients.
  • Embodiments of the dosage form may include one or more of the following features.
  • a seal coating may be included between the core and the first coating surrounding the core.
  • the seal coating may include one or more water soluble polymers for example, hydroxypropylmethylcellulose and hydroxypropylcellulose.
  • the one or more pharmaceutically acceptable excipients may include one or more binders, fillers, plasticizers, and lubricants /glidants.
  • the binders may include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof.
  • the fillers may be microcrystalline cellulose.
  • the lubricants may include one or more of magnesium stearate, stearic acid, and glyceryl behenate.
  • the plasticizers may include one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1 ,2-propyleneglycol, dibutylsebacate, diethylsebacate, and mixtures thereof.
  • the coating on the core may include one or more polymers that may be permeable to gastrointestinal fluids but insoluble in the same.
  • polymers include cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like.
  • the enteric coating may include one or more enterosoluble polymers.
  • the enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine.
  • the enteric layer may serve to protect the drug from gastric contents.
  • enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
  • the coatings may optionally contain one or more excipients such as plasticizers, lubricants, glidant anti-adherents for example, magnesium stearate, talc, colloidal silicon dioxide, silicon dioxide, inert fillers, and pigments.
  • Silicon dioxide may additionally function as a wicking agent for fluids from the external media into the core.
  • a process for the preparation of extended release dosage forms of bupropion hydrochloride includes preparing a core, and coating the core with a layer. The process also includes optionally coating the core with a seal coat and/or the coating surrounding the core with an enteric layer.
  • the core may be prepared by granulating bupropion hydrochloride, and, optionally mixing with one or more pharmaceutically acceptable excipients and compressing.
  • the core may be coated with a layer formed by a substantially water- insoluble film forming polymers, channeling agents and, optionally, pharmaceutically acceptable excipients.
  • a method of treating depression or nicotine addiction includes administering an extended release dosage form that includes a core, and a coating on the core.
  • the core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents.
  • the coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients.
  • the dosage form may include a seal coating which may be applied between the core and the coating surrounding the core.
  • the seal coating may include one or more water soluble polymers like hydroxypropylmethylcellulose and hydroxypropylcellulose.
  • the enteric coating may include one or more enterosoluble polymers.
  • the details of various embodiments of the inventions are set forth in the accompanying description below. Other features and advantages of the inventions will be apparent from the description and the claims. Detailed Description of the Invention As described in detail herein, the inventors have discovered that extended release dosage forms of bupropion hydrochloride may be formulated without the need for osmotic enhancing agents. For example, the inventors have developed an extended release dosage form that includes a core, and a coating on the core. The core includes bupropion hydrochloride and, optionally pharmaceutically acceptable excipients. The core is characterized as being free of osmotic enhancing agents.
  • the core is coated with a layer that includes water-insoluble film forming polymers and, optionally, one or more pharmaceutically acceptable excipients.
  • a seal coating may be applied between the core and the coating surrounding the core.
  • the inventors also have developed an extended release dosage form that includes a core, a first coating on the core and a second enteric coating surrounding the first coating.
  • the core includes bupropion hydrochloride and, optionally pharmaceutically acceptable excipients.
  • the core is characterized as being free of osmotic enhancing agents.
  • a seal coating may be applied between the core and the first coating surrounding the core.
  • the core containing bupropion hydrochloride can be prepared by either directly compressing, wet granulating or dry granulating a mixture of bupropion hydrochloride and other excipients like binders, fillers and lubricants/glidants.
  • One process to formulate the extended release dosage form includes preparing a core and coating the core. To prepare the core, bupropion hydrochloride and, optionally one or more pharmaceutically acceptable excipients are dispersed in purified water, one or more solvents, or mixtures thereof to obtain dispersion. The dispersion is spray dried, mixed with optional pharmaceutically acceptable excipients, and compressed to form cores.
  • the core then is coated with a layer that is formed from substantially water- insoluble film forming polymers and optional pharmaceutically acceptable excipients.
  • the coated core then may be coated with an enteric coating.
  • the core may also be coated with a seal coating between the core and the coating surrounding the core.
  • the amount of bupropion hydrochloride may vary from about 5 mg to about
  • the core as used herein refers to any structure that is enclosed or surrounded by a coating or equivalent.
  • the core may be in the form of a tablet, pellet, or mixture thereof.
  • the term 'pellets' as used herein may include one or more of granules, beads, pellets, slugs or mixtures thereof.
  • the core may contain one or more pharmaceutically acceptable excipients, including one or more of binders, fillers, and lubricants/glidants. Suitable binders include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof.
  • Suitable fillers include microcrystalline cellulose.
  • Suitable lubricants include one or more of magnesium stearate, stearic acid, and glyceryl behenate.
  • the preferred range of lubricants in the formulation depends on the type of formulations to be prepared as disclosed in various examples contained herein.
  • the various coating layers can then be applied on the compressed core by conventional coating techniques like spray drying, pan coating, etc. well known to a person skilled in the art.
  • the solvents used in preparing solution or dispersion of coating compositions can be aqueous or organic or a mixture of both.
  • the suitable solvents include water, dichlorom ethane, isopropyl alcohol, methanol, acetone, and mixtures of isopropyl alcohol with dichloromethane or water.
  • the solvent system used in preparing water insoluble coating containing channeling agents is prepared in organic solvent in which channeling agent is insoluble such as acetone, dichloromethane, isopropyl alcohol and mixtures thereof.
  • the coating surrounding the core is made up of substantially water-insoluble film forming polymers, channeling agents and, optionally, plasticizers.
  • the coating may contain one or more pharmaceutically acceptable excipients.
  • the substantially water- insoluble film forming polymers may be selected from cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like.
  • the drug may be released from the core due to the presence of water-soluble channeling agents in the coating, which upon dissolution may form a porous membrane through which the drug could diffuse out.
  • channeling agents examples include lactose, sucrose, sorbitol, mannitol, sodium chloride, calcium chloride, potassium chloride, and the like.
  • the range of the channeling agents in the formulations depends on the type of formulations prepared and will be apparent to one skilled in the art based on the various examples disclosed in the specification.
  • the coating surrounding the core may be coated with a layer containing enterosoluble polymers.
  • the enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine.
  • the enteric layer may serve to protect the drug from gastric contents.
  • enteric polymers examples include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
  • the extended release dosage form is capable of delivering bupropion hydrochloride at a predictable rate.
  • the dosage form may maintain therapeutic plasma levels of bupropion from about 12 to 24 hours. Accordingly, the dosage form may be designed to be given once or twice daily.
  • Bupropion hydrochloride was granulated with an aqueous solution of polyvinyl alcohol in a fluidized bed granulator. The granules were dried and sized. The sized granules were lubricated with magnesium stearate, glyceryl behenate and colloidal silicon dioxide and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylmethylcellulose and triethyl citrate dissolved in purified water was applied to the compressed cores as a seal coating.
  • coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: water (95:5) mixture. Finally, these coated cores were coated with an enteric coating dispersion containing Eudragit L30 D 55, triethyl citrate, silicon dioxide and polyethylene glycol dispersed in purified water.
  • Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose and triethyl citrate in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • the coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, lactose monohydrate and hydroxypropylmethylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
  • Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • the coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, lactose monohydrate and hydroxypropylmethylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
  • Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate, lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
  • Bupropion hydrochloride was granulated with hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator.
  • the granules were dried, sized and lubricated with glyceryl behenate and compressed into tablet cores using appropriate tooling.
  • the compressed cores were loaded in a pan coater and a solution of hydroxypropylmethylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating.
  • coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate, lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: water mixture (95:5). Finally, these coated cores were coated with an enteric coating dispersion containing Eudragit L30 D 55, triethyl citrate, silicon dioxide and polyethylene glycol dispersed in purified water.
  • Example 6 Dissolution profiles of tablets of examples 1-5 as measured in a USP type I dissolution apparatus, at 75 rpm, at a temperature of 37 ⁇ 0.5°C in 900ml of 0.01N hydrochloric acid

Abstract

The present invention relates to extended release dosage forms of bupropion hydrochloride and processes for their preparation. The dosage form includes a core, and a coating on the core. The core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents. The coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents, plasticizers and, optionally, one or more pharmaceutically acceptable excipients.

Description

EXTENDED RELEASE DOSAGE FORMS OF BUPROPION HYDROCHLORIDE Field of the invention The present invention relates to extended release dosage forms of bupropion hydrochloride and processes for their preparation. Background of the Invention Bupropion hydrochloride is a well-known antidepressant and non-nicotine aid to smoking cessation. It has been observed that bupropion hydrochloride when taken in an immediate release dosage form has the risk of inducing seizures in patients. This side effect is attributed to the sudden high peak plasma concentration produced by these immediate release dosage forms. The incidences of seizures can be subsided by designing a dosage form of bupropion hydrochloride with extended release properties so that sudden high peak plasma concentration is avoided. U.S. Patent No. 4,687,660 discloses a controlled release dosage form powered by an osmotic pumping mechanism. The dosage form comprises a core containing bupropion hydrochloride and osmotic enhancing agent in an amount equal to or greater than bupropion hydrochloride. The core is coated with a semi-permeable polymeric film consisting of water insoluble, water permeable polymer, channeling agents which dissolve in the gastrointestinal fluids and provide passage for the release of drug from the core. The drug release from the core is driven by osmotic pressure. This type of dosage form has the disadvantage that there is always a risk of dose dumping in case too much pressure is built up in the core and the dosage form may burst releasing the entire drug at once which may also precipitate a seizure. Further, the release from such an osmotic dosage form may not be uniform as the drug release is governed by the osmotic pressure developed inside the core which may be variable. A dosage form which can deliver bupropion in an extended release form without using an osmotic enhancing agent is desirable. It is conceived that by devising a core free of osmotic enhancing agent, a uniform and predictable extended release of bupropion may be obtained. Summary of the Invention In one general aspect there is provided an extended release dosage form of bupropion hydrochloride. The dosage form includes a core, and a coating on the core. The core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents. The coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients. Embodiments of the dosage form may include one or more of the following features. For example, a seal coating may be included between the core and the coating surrounding the core. The seal coating may include one or more water soluble polymers for example, hydroxypropylmethylcellulose and hydroxypropylcellulose. The one or more pharmaceutically acceptable excipients may include one or more binders, fillers, plasticizers, and lubricants /glidants. The binders may include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof. The fillers may be microcrystalline cellulose. The lubricants may include one or more of magnesium stearate, stearic acid, and glyceryl behenate. The plasticizers may include one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1,2-propyleneglycol, dibutylsebacate, diethylsebacate, and mixtures thereof. The coating on the core may include one or more polymers that may be permeable to gastrointestinal fluids but insoluble in the same. Examples of such polymers include cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like. In another general aspect, an enteric coating may be applied outside the coating surrounding the core. The enteric coating may include one or more enterosoluble polymers. The enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine. The enteric layer may serve to protect the drug from gastric contents. Examples of enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac. The coatings may optionally contain one or more excipients such as plasticizers, lubricants, glidant anti-adherents for example, magnesium stearate, talc, colloidal silicon dioxide, silicon dioxide, inert fillers, and pigments. Silicon dioxide may additionally function as a wicking agent for fluids from the external media into the core. In another general aspect there is provided an extended release dosage form of bupropion hydrochloride. The dosage form includes a core, a first coating on the core and a second enteric coating surrounding the first coating. The core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents. The first coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients. The second enteric coating surrounds the first coating and includes one or more enterosoluble polymers and, optionally, one or more pharmaceutically acceptable excipients. Embodiments of the dosage form may include one or more of the following features. For example, a seal coating may be included between the core and the first coating surrounding the core. The seal coating may include one or more water soluble polymers for example, hydroxypropylmethylcellulose and hydroxypropylcellulose. The one or more pharmaceutically acceptable excipients may include one or more binders, fillers, plasticizers, and lubricants /glidants. The binders may include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof. The fillers may be microcrystalline cellulose. The lubricants may include one or more of magnesium stearate, stearic acid, and glyceryl behenate. The plasticizers may include one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1 ,2-propyleneglycol, dibutylsebacate, diethylsebacate, and mixtures thereof. The coating on the core may include one or more polymers that may be permeable to gastrointestinal fluids but insoluble in the same. Examples of such polymers include cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like. The enteric coating may include one or more enterosoluble polymers. The enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine. The enteric layer may serve to protect the drug from gastric contents. Examples of enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac. The coatings may optionally contain one or more excipients such as plasticizers, lubricants, glidant anti-adherents for example, magnesium stearate, talc, colloidal silicon dioxide, silicon dioxide, inert fillers, and pigments. Silicon dioxide may additionally function as a wicking agent for fluids from the external media into the core. In another general aspect, there is provided a process for the preparation of extended release dosage forms of bupropion hydrochloride. The process includes preparing a core, and coating the core with a layer. The process also includes optionally coating the core with a seal coat and/or the coating surrounding the core with an enteric layer. The core may be prepared by granulating bupropion hydrochloride, and, optionally mixing with one or more pharmaceutically acceptable excipients and compressing. The core may be coated with a layer formed by a substantially water- insoluble film forming polymers, channeling agents and, optionally, pharmaceutically acceptable excipients. In another general aspect, there is provided a method of treating depression or nicotine addiction. The method includes administering an extended release dosage form that includes a core, and a coating on the core. The core includes bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents. The coating surrounds the core and includes one or more water-insoluble film forming polymers, channeling agents and, optionally, one or more pharmaceutically acceptable excipients. The dosage form may include a seal coating which may be applied between the core and the coating surrounding the core. The seal coating may include one or more water soluble polymers like hydroxypropylmethylcellulose and hydroxypropylcellulose. It may also include an enteric coating which may be applied outside the coating surrounding the core. The enteric coating may include one or more enterosoluble polymers. The details of various embodiments of the inventions are set forth in the accompanying description below. Other features and advantages of the inventions will be apparent from the description and the claims. Detailed Description of the Invention As described in detail herein, the inventors have discovered that extended release dosage forms of bupropion hydrochloride may be formulated without the need for osmotic enhancing agents. For example, the inventors have developed an extended release dosage form that includes a core, and a coating on the core. The core includes bupropion hydrochloride and, optionally pharmaceutically acceptable excipients. The core is characterized as being free of osmotic enhancing agents. The core is coated with a layer that includes water-insoluble film forming polymers and, optionally, one or more pharmaceutically acceptable excipients. A seal coating may be applied between the core and the coating surrounding the core. The inventors also have developed an extended release dosage form that includes a core, a first coating on the core and a second enteric coating surrounding the first coating. The core includes bupropion hydrochloride and, optionally pharmaceutically acceptable excipients. Moreover, the core is characterized as being free of osmotic enhancing agents. A seal coating may be applied between the core and the first coating surrounding the core. The core containing bupropion hydrochloride can be prepared by either directly compressing, wet granulating or dry granulating a mixture of bupropion hydrochloride and other excipients like binders, fillers and lubricants/glidants. One process to formulate the extended release dosage form includes preparing a core and coating the core. To prepare the core, bupropion hydrochloride and, optionally one or more pharmaceutically acceptable excipients are dispersed in purified water, one or more solvents, or mixtures thereof to obtain dispersion. The dispersion is spray dried, mixed with optional pharmaceutically acceptable excipients, and compressed to form cores. The core then is coated with a layer that is formed from substantially water- insoluble film forming polymers and optional pharmaceutically acceptable excipients. The coated core then may be coated with an enteric coating. The core may also be coated with a seal coating between the core and the coating surrounding the core. The amount of bupropion hydrochloride may vary from about 5 mg to about
500 mg and preferably from about 150 mg to about 300 mg. The core as used herein refers to any structure that is enclosed or surrounded by a coating or equivalent. The core may be in the form of a tablet, pellet, or mixture thereof. The term 'pellets' as used herein may include one or more of granules, beads, pellets, slugs or mixtures thereof. The core may contain one or more pharmaceutically acceptable excipients, including one or more of binders, fillers, and lubricants/glidants. Suitable binders include one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and combinations thereof. The preferred range of binders in the formulation depends on the type of formulations to be prepared as disclosed in various examples contained herein. Suitable fillers include microcrystalline cellulose. Suitable lubricants include one or more of magnesium stearate, stearic acid, and glyceryl behenate. The preferred range of lubricants in the formulation depends on the type of formulations to be prepared as disclosed in various examples contained herein. The various coating layers can then be applied on the compressed core by conventional coating techniques like spray drying, pan coating, etc. well known to a person skilled in the art. The solvents used in preparing solution or dispersion of coating compositions can be aqueous or organic or a mixture of both. The suitable solvents include water, dichlorom ethane, isopropyl alcohol, methanol, acetone, and mixtures of isopropyl alcohol with dichloromethane or water. The solvent system used in preparing water insoluble coating containing channeling agents is prepared in organic solvent in which channeling agent is insoluble such as acetone, dichloromethane, isopropyl alcohol and mixtures thereof. The coating surrounding the core is made up of substantially water-insoluble film forming polymers, channeling agents and, optionally, plasticizers. The coating may contain one or more pharmaceutically acceptable excipients. The substantially water- insoluble film forming polymers may be selected from cellulose derivatives such as ethylcellulose; polyvinyl acetate; neutral copolymers based on ethyl acrylate and methylmethacrylate; copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups such as Eudragit NE, RS or RS30D, RL or RL30D; and the like. The drug may be released from the core due to the presence of water-soluble channeling agents in the coating, which upon dissolution may form a porous membrane through which the drug could diffuse out. Examples of such channeling agents include lactose, sucrose, sorbitol, mannitol, sodium chloride, calcium chloride, potassium chloride, and the like. The range of the channeling agents in the formulations depends on the type of formulations prepared and will be apparent to one skilled in the art based on the various examples disclosed in the specification. The coating surrounding the core may be coated with a layer containing enterosoluble polymers. The enterosoluble polymers may include polymers which are insoluble in the pH of the stomach but are soluble in the pH of the intestine. The enteric layer may serve to protect the drug from gastric contents. Examples of enteric polymers include esters of cellulose and its derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate; pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac. The extended release dosage form is capable of delivering bupropion hydrochloride at a predictable rate. The dosage form may maintain therapeutic plasma levels of bupropion from about 12 to 24 hours. Accordingly, the dosage form may be designed to be given once or twice daily. The following examples illustrate various embodiments and do not limit the claims in any manner.
Example 1 :
Process: Bupropion hydrochloride was granulated with an aqueous solution of polyvinyl alcohol in a fluidized bed granulator. The granules were dried and sized. The sized granules were lubricated with magnesium stearate, glyceryl behenate and colloidal silicon dioxide and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylmethylcellulose and triethyl citrate dissolved in purified water was applied to the compressed cores as a seal coating. The coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: water (95:5) mixture. Finally, these coated cores were coated with an enteric coating dispersion containing Eudragit L30 D 55, triethyl citrate, silicon dioxide and polyethylene glycol dispersed in purified water.
Example 2:
Process: Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator. The granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose and triethyl citrate in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating. The coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, lactose monohydrate and hydroxypropylmethylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
Example 3 :
Process: Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator. The granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating. The coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, lactose monohydrate and hydroxypropylmethylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
Example 4:
Process: Bupropion hydrochloride was granulated with a solution of hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator. The granules were dried, sized and lubricated with stearic acid and glyceryl behenate and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating. The coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate, lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: dichloromethane mixture (60:40).
Example 5:
Process: Bupropion hydrochloride was granulated with hydroxypropylcellulose dissolved in isopropyl alcohol: dichloromethane mixture (60:40) in a fluidized bed granulator. The granules were dried, sized and lubricated with glyceryl behenate and compressed into tablet cores using appropriate tooling. The compressed cores were loaded in a pan coater and a solution of hydroxypropylmethylcellulose in isopropyl alcohol: dichloromethane mixture (60:40) was applied to the compressed cores as a seal coating. The coated cores were dried and coated with a water insoluble coating containing ethyl cellulose, triethyl citrate, lactose monohydrate and polyvinylpyrrolidone dissolved in isopropyl alcohol: water mixture (95:5). Finally, these coated cores were coated with an enteric coating dispersion containing Eudragit L30 D 55, triethyl citrate, silicon dioxide and polyethylene glycol dispersed in purified water.
Example 6: Dissolution profiles of tablets of examples 1-5 as measured in a USP type I dissolution apparatus, at 75 rpm, at a temperature of 37±0.5°C in 900ml of 0.01N hydrochloric acid
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.

Claims

We claim:
1. An extended release dosage form of bupropion hydrochloride, the dosage form comprising: a) a core comprising bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents; and b) a coating surrounding the core and comprising a water-insoluble film forming polymer, a channeling agent and, optionally, one or more pharmaceutically acceptable excipients.
2. The extended release dosage form of claim 1, comprising from about 5 mg to about 500 mg bupropion hydrochloride.
3. The extended release dosage form of claim 2, comprising about 150 mg bupropion hydrochloride.
4. The extended release dosage form of claim 2, comprising about 300 mg bupropion hydrochloride.
5. The extended release dosage form of claim 1, wherein the water-insoluble polymer comprises one or more of ethylcellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methacrylate copolymers of acrylic acid and methacrylic acid esters with quaternary ammonium groups.
6. The extended release dosage form of claim 5, wherein the water insoluble polymer is ethyl cellulose.
7. The extended release dosage form of claim 1, wherein the channeling agent comprises one or more of lactose, sucrose, sorbitol, mannitol, sodium chloride and potassium chloride.
8. The extended release dosage form of claim 7, wherein the channeling agent is lactose.
9. The extended release dosage form of claim 1, wherein the pharmaceutically acceptable excipients comprise one or more of binders, fillers, plasticizers and lubricants/ glidants.
10. The extended release dosage form of claim 9, wherein the binder comprises one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and mixtures thereof.
11. The extended release dosage form of claim 9, wherein the filler is microcrystalline cellulose.
12. The extended release dosage form of claim 9, wherein the plasticizer comprises one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1,2-propyleneglycol, dibutylsebacate, diethylsebacate and mixtures thereof.
13. The extended release dosage form of claim 9, wherein the lubricant comprises one or more of magnesium stearate, stearic acid and glyceryl behenate.
14. The extended release dosage form of claim 1, further comprising a seal coating between the core and the coating surrounding the core.
15. The extended release dosage form of claim 14, wherein the seal coating comprises one or more of water soluble polymers and, optionally other pharmaceutically acceptable excipients.
16. The extended release dosage form of claim 15, wherein the water soluble polymer comprises one or both of hydroxypropylmethylcellulose and hydroxypropylcellulose.
17. The extended release dosage form of claim 15, wherein the other pharmaceutically acceptable excipients comprise one or more of plasticizers, lubricants, glidant anti- adherents, inert fillers, and pigments.
18. The extended release dosage form of claim 1, further comprising an outer enteric coating over the coating surrounding the core.
19. The extended release dosage form of claim 18, wherein the enteric coating comprises one or more of enterosoluble polymers and, optionally other pharmaceutically acceptable excipients.
20. The extended release dosage form of claim 19, wherein the enterosoluble polymer comprises one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, pH-sensitive methacrylic acid-methamethacrylate copolymers and shellac.
21. The extended release dosage form of claim 20, wherein the other pharmaceutically acceptable excipients comprise one or more of plasticizers, lubricants, glidant anti- adherents, inert fillers, and pigments.
22. The extended release dosage form of claim 1, wherein the dosage form comprises one or more of tablets, granules, and pellets.
23. An extended release dosage form of bupropion hydrochloride, the dosage form comprising: a) a core comprising bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents; b) a first coating surrounding the core and comprising a water-insoluble film forming polymer, a channeling agent and, optionally, one or more pharmaceutically acceptable excipients; and c) a second enteric coating surrounding the first coating and comprising an enterosoluble polymers and, optionally, one or more pharmaceutically acceptable excipients.
24. The extended release dosage form of claim 23, comprising from about 5 mg to about 500 mg bupropion hydrochloride.
25. The extended release dosage form of claim 24, comprising about 150 mg bupropion hydrochloride.
26. The extended release dosage form of claim 24, comprising about 300 mg bupropion hydrochloride.
27. The extended release dosage form of claim 23, wherein the water-insoluble polymer comprises one or more of ethylcellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methacrylate copolymers of acrylic acid and methacrylic acid esters with quaternary ammonium groups.
28. The extended release dosage form of claim 27, wherein the water insoluble polymer is ethyl cellulose.
29. The extended release dosage form of claim 23, wherein the channeling agent comprises one or more of lactose, sucrose, sorbitol, mannitol, sodium chloride and potassium chloride.
30. The extended release dosage form of claim 29, wherein the channeling agent is lactose.
31. The extended release dosage form of claim 23, wherein the pharmaceutically acceptable excipients comprise one or more of binders, fillers, plasticizers, and lubricants/ glidants.
32. The extended release dosage form of claim 31, wherein the binder comprises one or more of polyvinylpyrrolidone, polyvinyl alcohol, copolyvidone, hydroxypropylcellulose, hydroxypropylmethylcellulose and mixtures thereof.
33. The extended release dosage form of claim 31 , wherein the filler is microcrystalline cellulose.
34. The extended release dosage form of claim 31 , wherein the plasticizer comprises one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propylene glycol, 1 ,2-propyleneglycol, dibutylsebacate, diethylsebacate and mixtures thereof.
35. The extended release dosage form of claim 31, wherein the lubricant comprises one or more of magnesium stearate, stearic acid and glyceryl behenate.
36. The extended release dosage form of claim 23, further comprising a seal coating between the core and the first coating surrounding the core.
37. The extended release dosage form of claim 36, wherein the seal coating comprises one or more of water soluble polymers and, optionally other pharmaceutically acceptable excipients.
38. The extended release dosage form of claim 37, wherein the water-soluble polymer comprises one or both of hydroxypropylcellulose or hydroxypropyl methylcellulose.
39. The extended release dosage form of claim 37, wherein the other pharmaceutically acceptable excipients comprise one or more of plasticizers, lubricants, glidant anti- adherents, inert fillers, and pigments.
40. The extended release form of claim 23, wherein the dosage form comprises one or more of tablets, granules, and pellets.
41. A method of treating depression or nicotine addiction, the method of treating comprising administering an extended release dosage form of bupropion hydrochloride, the extended release dosage form comprising: a) a core comprising bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents; and b) a coating surrounding the core and comprising a water-insoluble film forming polymer, a channeling agent and, optionally, one or more pharmaceutically acceptable excipients.
42. The method of claim 41, comprising from about 5 mg to about 500 mg bupropion hydrochloride.
43. The method of claim 41, wherein the water-insoluble polymer comprises one or more of ethylcellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methacrylate copolymers of acrylic acid and methacrylic acid esters with quaternary ammonium groups.
44. The method of claim 41, wherein the channeling agent comprises one or more of lactose, sucrose, sorbitol, mannitol, sodium chloride and potassium chloride.
45. The method of claim 41, wherein the pharmaceutically acceptable excipients comprise one or more of binders, fillers, plasticizers, and lubricants/glidants.
46. The method of claim 45, wherein the plasticizer comprises one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, and mixtures thereof.
47. The method of claim 41, further comprising a seal coating between the core and the coating surrounding the core.
48. The method of claim 47, wherein the seal coating comprises one or more of water soluble polymers and, optionally, other pharmaceutically acceptable excipients.
49. The method of claim 48, wherein the water soluble polymer comprises one or both of hydroxypropylmethylcellulose and hydroxypropylcellulose.
50. The method of claim 41, further comprising an outer enteric coating over the coating surrounding the core.
51. The method of claim 50, wherein the enteric coating comprises one or more of enterosoluble polymers and, optionally, other pharmaceutically acceptable excipients.
52. The method of claim 51, wherein the enterosoluble polymer comprises one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, pH- sensitive methacrylic acid-methamethacrylate copolymers and shellac.
53. The method of claim 41, wherein the dosage form comprises one or more of tablets, granules, and pellets.
54. A process for the preparation of an extended release dosage form of bupropion hydrochloride, the process comprising: a) providing a core comprising bupropion hydrochloride and, optionally, one or more pharmaceutically acceptable excipients, wherein the core is free of osmotic enhancing agents; and b) coating the core, the coating comprising a water-insoluble film forming polymer, a channeling agent and, optionally, one or more pharmaceutically acceptable excipients.
55. The process of claim 54, wherein the core is prepared by direct compression or granulation.
56. The process of claim 55, wherein the core is prepared by dry granulation or wet granulation.
57. The process of claim 56, wherein the granulation process comprises wetting a dry mix of core material with or without other pharmaceutically acceptable excipients with a binder solution.
58. The process of claim 57, further comprising compressing granules into a suitable size core.
59. The process of claim 54, wherein the coating is applied on the core in powder form or sprayed as a solution or dispersion in a solvent.
60. The process of claim 54, wherein the solvent comprises one or more of water, alcohols, methyl alcohol, ethyl alcohol, isopropyl alcohol; ketones, acetone, ethylmethylketone; chlorinated hydrocarbons, dichloromethane, dichloroethane, trichloroethane, and mixtures thereof.
61. The process of claim 54, wherein the water-insoluble polymer comprises one or more of ethylcellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methacrylate copolymers of acrylic acid and methacrylic acid esters with quaternary ammonium groups.
62. The process of claim 54, wherein the channeling agent comprises one or more of lactose, sucrose, sorbitol, mannitol, sodium chloride and potassium chloride.
63. The process of claim 54, wherein the pharmaceutically acceptable excipients comprise one or more of binders, fillers, plasticizers, and lubricants/glidants.
64. The process of claim 63, wherein the plasticizer comprises one or more of triacetin, acetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, and mixtures thereof.
65. The process of claim 54, further comprising applying a seal coating between the core and the coating surrounding the core.
66. The process of claim 65, wherein the seal coating comprises one or more of water soluble polymers and, optionally, other pharmaceutically acceptable excipients.
67. The process of claim 66, wherein the water soluble polymers comprises one or both of hydroxypropylmethylcellulose and hydroxypropylcellulose.
68. The process of claim 54, further comprising applying an outer enteric coating surrounding the coating over the core.
69. The process of claim 68, wherein the enteric coating comprises one or more of enterosoluble polymers and, optionally, other pharmaceutically acceptable excipients.
70. The process of claim 69, wherein the enterosoluble polymer comprises one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, pH- sensitive methacrylic acid-methamethacrylate copolymers and shellac.
EP04798903A 2003-11-21 2004-11-18 Extended release dosage forms of bupropion hydrochloride Withdrawn EP1686974A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1449DE2003 2003-11-21
PCT/IB2004/003778 WO2005049003A1 (en) 2003-11-21 2004-11-18 Extended release dosage forms of bupropion hydrochloride

Publications (1)

Publication Number Publication Date
EP1686974A1 true EP1686974A1 (en) 2006-08-09

Family

ID=34611193

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04798903A Withdrawn EP1686974A1 (en) 2003-11-21 2004-11-18 Extended release dosage forms of bupropion hydrochloride

Country Status (2)

Country Link
EP (1) EP1686974A1 (en)
WO (1) WO2005049003A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
CN110200947A (en) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 A kind of Bupropion enteric sustained-release pellet capsule and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
IN192747B (en) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005049003A1 *

Also Published As

Publication number Publication date
WO2005049003A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
JP6457458B2 (en) Timed pulse emission system
US6946146B2 (en) Coating for a sustained release pharmaceutical composition
CA2349696C (en) Controlled release formulation for water soluble drugs
CA2514879C (en) Two or more enteric materials to regulate drug release
US5830503A (en) Enteric coated diltiazem once-a-day formulation
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
AU2002248792A1 (en) A novel coating for a sustained release pharmaceutical composition
JPH072645A (en) Pharmaceutical preparation for ph-actuative permeation bursting release
EP1898886A2 (en) Novel sustained release dosage form
KR100591142B1 (en) A enteric sustained-release tablet comprising paroxetine
JP2014208655A (en) Extended-release dosage form
JP4540092B2 (en) Pharmaceutical composition containing bioactive compound unstable to acid and process for producing the same
WO2009069089A9 (en) Levetiracetam controlled release composition
EP3893851A1 (en) Solid oral pharmaceutical compositions for administration of mesalazine or derivatives thereof
WO2001080824A2 (en) Dual mechanism timed release dosage forms for low dose drugs
WO2008023390A2 (en) Modified release pharmaceutical composition of bupropion hydrochloride
CA2409721A1 (en) A coating composition for facilitating controlled release
JPH09504779A (en) Drug transfer composition for α-adrenoreceptor blocker
CA2685214C (en) Improved controlled release oral dosage form
WO2005049003A1 (en) Extended release dosage forms of bupropion hydrochloride
US20090186087A1 (en) Enteric sustained-release coated core and pharmaceutical dosage form and method for manufacturing the same
JP2018184360A (en) Enteric-coated sustained release formulation for oral administration
AU2014246617A1 (en) Multi-layered, multiple unit pharmaceutical compositions
AU2002253907A1 (en) Improved controlled release oral dosage form

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

D17P Request for examination filed (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

DAX Request for extension of the european patent (deleted)
18D Application deemed to be withdrawn

Effective date: 20060622

DBV Designated contracting states (deleted)